Drug & intervention

ziprasidone

RxCUI 115698

Clinical trials63
Recruiting0
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Ziprasidone

Ziprasidone, sold under the brand name Geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It may be used by mouth and by injection into a muscle (IM). The intramuscular form may be used for acute agitation in people with schizophrenia. Common side effects include tremors, tics, dizziness, dry mouth, restlessness, nausea, and mild sedation. Although it can also cause weight gain, the risk is much lower than for other atypical antipsychotics. How it works is not entirely clear but is believed to involve effects on serotonin and dopamine in the brain. Ziprasidone was approved for medical use in the United States in 2001. The pills are made up of the hydrochloride salt, ziprasidone hydrochloride. The intramuscular form is the mesylate, ziprasidone mesylate trihydrate, and is provided as a lyophilized powder. In 2020, it was the 282nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model BuildingNCT04446234 · 2021-05-01
UNKNOWN
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic MedicationNCT03557931 · 2018-07-13
COMPLETED
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For SchizophreniaNCT03781115 · 2017-11-20
ACTIVE_NOT_RECRUITING
The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic AgitationNCT02935998 · 2016-10-01
UNKNOWN
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)NCT02600741 · 2015-07-24
COMPLETED
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsNCT02307396 · 2015-02-01
COMPLETED
Pharmacovigilance in Gerontopsychiatric PatientsNCT02374567 · 2015-01-01
TERMINATED
The Role of miR-30 Family Dysregulation in Response to Antipsychotic TreatmentNCT02650102 · 2013-01-01
UNKNOWN
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for SchizophreniaNCT02192723 · 2012-06-01
COMPLETED
Effectiveness of Ziprasidone for Patients With SchizophreniaNCT01198353 · 2010-09-01
COMPLETED
Antipsychotics and Gene Expression in Soft TissuesNCT01185743 · 2010-07-01
COMPLETED
Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive DisorderNCT01168674 · 2010-02-01
COMPLETED
Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic SyndromeNCT01714011 · 2009-05-01
COMPLETED
Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial CapsulesNCT00821444 · 2009-01-01
COMPLETED
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-upNCT02526030 · 2008-10-01
COMPLETED
Ziprasidone vs Standard Therapy for Agitated Patients in the EDNCT00786318 · 2008-09-01
WITHDRAWN
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIsNCT00633399 · 2008-07-01
COMPLETED
Ziprasidone in the Psychosis ProdromeNCT00635700 · 2008-03-01
COMPLETED
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive DisorderNCT00555997 · 2008-03-01
COMPLETED
Treatment of Schizophrenic Patients With ZiprasidoneNCT00579670 · 2007-10-01
COMPLETED
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to ZiprasidoneNCT00538642 · 2007-08-01
COMPLETED
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.NCT00454883 · 2007-04-01
COMPLETED
Switch Study of Existing Atypical Antipsychotics to BifeprunoxNCT00347425 · 2006-12-01
COMPLETED
Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To ZiprasidoneNCT00406315 · 2006-11-01
COMPLETED
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating EfficacyNCT00330863 · 2006-05-01
COMPLETED
Open-label Ziprasidone Study for Psychosis Treatment in AdolescentsNCT00421954 · 2006-05-01
COMPLETED
Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)NCT00229385 · 2006-01-01
COMPLETED
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaNCT00254202 · 2005-11-18
COMPLETED
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective PsychosisNCT02305823 · 2005-10-01
COMPLETED
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-upNCT02534363 · 2005-10-01
COMPLETED
A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox CapsuleNCT01053429 · 2005-06-01
COMPLETED
Efficacy and Tolerability of Switching to Ziprasidone From Other AntipsychoticsNCT00458211 · 2005-05-01
COMPLETED
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major DepressionNCT00237666 · 2005-02-01
COMPLETED
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes MellitusNCT00351000 · 2005-01-01
COMPLETED
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective DisorderNCT00137020 · 2004-11-01
COMPLETED
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective DisorderNCT00645229 · 2004-09-01
TERMINATED
A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese PatientsNCT00645372 · 2004-07-01
COMPLETED
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized PatientsNCT00634348 · 2004-04-01
COMPLETED
Energy Homeostasis Under Treatment With Atypical AntipsychoticsNCT00148564 · 2004-03-01
COMPLETED
A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic DisordersNCT00650611 · 2003-12-01
COMPLETED

Leading sponsors

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.